| |
| | Cisplatin 1mg/ml Injection BP (Wockhardt UK Ltd) , SPC from the eMC |
 | | The cisplatin dosage depends on the primary disease, the expected reaction, and on whether cisplatin is used for monotherapy or as a component of a combination chemotherapy. |
 | | Neurotoxicity caused by cisplatin is characterised by peripheral neuropathy (typically bilateral and sensory), and rarely by the loss of taste or tactile function, or by retrobulbar neuritis with loss of sight and cerebral dysfunction (confusion, slurred speech, individual cases of cortical blindness, loss of memory, paralysis). |
 | | Following cisplatin doses of 20 to 120 mg/m², the concentrations of platinum are highest in liver, prostate and kidney, somewhat lower in bladder, muscles, testicle, pancreas and spleen and lowest in bowel, adrenal, heart, lung, cerebrum and cerebellum. |
| emc.medicines.org.uk /emc/assets/c/html/displaydoc.asp?DocumentID=10742 (3431 words) |
|